A Practical lens for Board Members - Will this PI Founder still be CEO by Series B? Most European life sciences funds back companies where the founding CEO is a first‑time scientific leader: a PI out of a top lab, an ex‑pharma director, sometimes a computational founder with limited management experience. Very few investment memos say, “And we expect to replace them before Series B.” Yet that’s exactly what happens in a lot of cases—not always for the wrong reasons, but often

Your first five hires will decide whether your “platform biotech” ever becomes more than a pitch deck. In the first 18 months you’re not building an org chart, you’re building an engine: one person who truly owns the platform, one who runs everything that isn’t science, one who turns data into a scalable system, an early regulatory voice to stop you tripping over yourself later, and a business partner who keeps capital and deals flowing.

Fractional vs Interim in Life Sciences – Not the Same Thing I’m seeing more life sciences organisations explore fractional senior roles – and they’re often confused with interim roles. Interim: usually full‑time, time‑limited, covering a defined role for a fixed period. Fractional: usually part‑time, longer-term, adding senior expertise for a set number of days or hours without owning the whole role. In a milestone‑driven, resource‑constrained environment, fractional models